ArticleEuropean journal of heart failure2021

Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.

Thomas Mondritzki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.